{
    "data": [
        {
            "id": "4226640",
            "type": "article",
            "attributes": {
                "publishOn": "2018-12-06T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cancer Research Highlight: Bristol-Myers And Seattle Genetics Put The Full Court Press On Aggressive Lymphoma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "308",
                            "type": "sentiment"
                        },
                        {
                            "id": "309",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4226640-cancer-research-highlight-bristol-myers-and-seattle-genetics-put-full-court-press-on"
            }
        },
        {
            "id": "4225021",
            "type": "article",
            "attributes": {
                "publishOn": "2018-11-29T08:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cancer Research Highlight: Bristol's Barnstorm Of Bad News Clouds Their Hopes In Small Cell Lung Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4225021-cancer-research-highlight-bristols-barnstorm-of-bad-news-clouds-hopes-in-small-cell-lung"
            }
        },
        {
            "id": "4216231",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-30T22:27:47-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "BMS Is A Buy On The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104054",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "21280",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4216231-bms-is-buy-on-dip"
            }
        },
        {
            "id": "4215545",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-29T15:59:02-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Recent Purchase: Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "238072",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4215545-recent-purchase-bristol-myers-squibb"
            }
        },
        {
            "id": "4211700",
            "type": "article",
            "attributes": {
                "publishOn": "2018-10-15T13:27:13-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cancer Research Highlight: Yet Again, It's Bristol Drawing The Short Stick In Lung Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "20790",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4211700-cancer-research-highlight-yet-again-bristol-drawing-short-stick-in-lung-cancer"
            }
        },
        {
            "id": "4204468",
            "type": "article",
            "attributes": {
                "publishOn": "2018-09-06T09:18:19-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And NASH: Where Do We Stand?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4204468-bristol-myers-squibb-and-nash-where-stand"
            }
        },
        {
            "id": "4202757",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-29T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Cancer Highlight: Clovis Looks To Capture Deeper Relevance With Bristol-Myers Collab",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "201259",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4202757-your-cancer-highlight-clovis-looks-to-capture-deeper-relevance-bristol-myers-collab"
            }
        },
        {
            "id": "4202368",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-27T16:17:22-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Yervoy's Resurgence Will Gain Momentum",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "19091",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4202368-why-yervoys-resurgence-will-gain-momentum"
            }
        },
        {
            "id": "4201775",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-24T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Cancer Research Highlight: Bristol-Myers Looks For An In To Earlier Multiple Myeloma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18971",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4201775-your-cancer-research-highlight-bristol-myers-looks-for-in-to-earlier-multiple-myeloma"
            }
        },
        {
            "id": "4201466",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-23T08:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Cancer Highlight: The Study That Could Bridge The New Key Competitors In Kidney Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "201249",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4201466-your-cancer-highlight-study-bridge-new-key-competitors-in-kidney-cancer"
            }
        },
        {
            "id": "4200363",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-19T13:02:02-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Your Daily Pharma Scoop: Opdivo Is Approved On SCLC, Mateon Trial On Hold, Tandem Product Launch",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4200363-your-daily-pharma-scoop-opdivo-is-approved-on-sclc-mateon-trial-on-hold-tandem-product-launch"
            }
        },
        {
            "id": "4198015",
            "type": "article",
            "attributes": {
                "publishOn": "2018-08-11T12:15:30-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "You Should Not Miss Bristol-Myers Squibb In 2018",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "18458",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4198015-you-should-not-miss-bristol-myers-squibb-in-2018"
            }
        },
        {
            "id": "4187020",
            "type": "article",
            "attributes": {
                "publishOn": "2018-07-13T01:14:34-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Oakmark Fund: Second Quarter 2018",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104204",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "576527",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4187020-oakmark-fund-second-quarter-2018"
            }
        },
        {
            "id": "4177534",
            "type": "article",
            "attributes": {
                "publishOn": "2018-05-27T13:54:55-04:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is One Stock That You Should Not Ignore",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "15703",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4177534-bristol-myers-squibb-is-one-stock-you-should-not-ignore"
            }
        },
        {
            "id": "4165171",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-24T11:01:46-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers And Exelixis Poise For Battle In Kidney Cancer - Who Will Emerge The Victor?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "93696",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "197173",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4165171-bristol-myers-and-exelixis-poise-for-battle-in-kidney-cancer-who-will-emerge-victor"
            }
        },
        {
            "id": "4163880",
            "type": "article",
            "attributes": {
                "publishOn": "2018-04-18T19:04:48-04:00",
                "isLockedPro": false,
                "commentCount": 174,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "I'm Buying Bristol-Myers Down Near 52-Week Lows",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4163880-buying-bristol-myers-down-near-52-week-lows"
            }
        },
        {
            "id": "4149028",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-21T14:43:56-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Sows Confusion",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4149028-bristol-myers-squibb-sows-confusion"
            }
        },
        {
            "id": "4148545",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-20T15:19:53-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Next Stop, Record Levels",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102683",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "12304",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4148545-bristol-myers-squibb-next-stop-record-levels"
            }
        },
        {
            "id": "4147507",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-16T00:08:58-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Looks For Growth Of Opdivo Beyond Development As A Single Agent",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4147507-bristol-myers-squibb-looks-for-growth-of-opdivo-beyond-development-single-agent"
            }
        },
        {
            "id": "4146945",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-15T02:59:17-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Pay Your Money And Hold Your Breath",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4146945-pay-your-money-and-hold-your-breath"
            }
        },
        {
            "id": "4143899",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-07T05:54:01-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Weaker Growth, Higher Valuation, Turning Cautious",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4143899-bristol-myers-weaker-growth-higher-valuation-turning-cautious"
            }
        },
        {
            "id": "4143525",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-06T11:23:46-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "U.S. Biotech/Pharma Sector Daily Observations Letter: February 5, 2018",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61851",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4143525-u-s-biotech-pharma-sector-daily-observations-letter-february-5-2018"
            }
        },
        {
            "id": "4143408",
            "type": "article",
            "attributes": {
                "publishOn": "2018-02-06T07:17:35-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Makes Enormous Advance In First-Line Lung Cancer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4143408-bristol-myers-squibb-makes-enormous-advance-in-first-line-lung-cancer"
            }
        },
        {
            "id": "4139072",
            "type": "article",
            "attributes": {
                "publishOn": "2018-01-22T09:06:16-05:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Abatacept Compared Against Aurinia Pharmaceuticals' Voclosporin In The Treatment Of Lupus Nephritis Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103416",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "196889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4139072-bristol-myers-squibbs-abatacept-compared-against-aurinia-pharmaceuticals-voclosporin-in"
            }
        }
    ]
}